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I read with interest the recent publication by Peitzsch et al. [1],
who evaluated liquid chromatography tandem mass spectrometry
(LC-MS/MS) for the measurement of free and deconjugated urine
metanephrines for the biochemical assessment of phaeochromocytoma
(PCC). Data presented clearly demonstrated the potential beneﬁts
of measuring free urine metanephrines instead or in addition to
deconjugated urine metanephrines (UMets). Speciﬁcally data showed
thatmedian free normetanephrine concentrationswere ten-fold higher
in patients with PCC compared to median concentrations observed
in the control group. No differences were observed between free and
deconjugated metanephrine levels. A similar publication by Pamporaki
et al. [2] conﬁrmed that plasma free normetanephrine levels, not
metanephrine are superior to deconjugated plasma normetanephrine
for the diagnosis of PCC. Data from this study showed that median con-
centrations of free normetanephrine were 17-fold higher in patients
with PCC than in the reference population, a 72% larger difference
than that for the 10-fold higher median concentrations of plasma
deconjugated normetanephrine.
In contrast Grouzmann [3] showed similar sensitivities and speci-
ﬁcities for plasma free metanephrines and deconjugated plasma and
urine metanephrines. Upper references limits for deconjugated plas-
ma metanephrines were also lower than those recently published
[2]. These differences in upper reference limits are thought to result
from patients at risk of PCC (e.g. incidentaloma, genetic predisposition
syndrome) and those taking anti-hypertensive medications being dis-
tinguished from healthy individuals.
The dilemma as to whether free or total fractionated metanephrines
should bemeasured in the biochemical assessment of PCC is not new [4].
In our laboratory we have measured free fractionated metanephrines
and catecholamines in urine by high performance liquid chromatogra-
phy with electrochemical detection (HPLC-ECD) for several years. This
is not in line with the recommendations from the ﬁrst International
Symposia for PCC [5]. The rational for perusing this approach is that
we believe that the free fraction is the form which is produced directly
in the chromafﬁn cell, though in the chromafﬁn cell tumour. Therefore
it is much more representative than sulphate conjugates which are a
product of sulphate transferase 1A3 (SULT1A3) enzyme action in the
gastrointestinal tract. Our upper cut-offs derived from the 97.5 percen-
tiles are higher than the preliminary data reported by Peitzsch [1], but
are in keepingwith previous authors [6] andmay be due to the differentAbbreviations: LC-MS/MS, liquid chromatography tandem mass spectrometry; PCC,
phaeochromocytoma; HPLC-ECD, high performance liquid chromatography with elec-
trochemical detection; UMets, urine metanephrines; IQC, internal quality control; EQA,
external quality assurance.
0009-8981 © 2013 The Author. Published by Elsevier B.V.
http://dx.doi.org/10.1016/j.cca.2013.05.018
Open access under CC BY-NC-ND license.populations studied and the improved speciﬁcity of measurement by
LC-MS/MS over HPLC-ECD.
The majority of laboratories in the United Kingdom measure
deconjugated fractionated urine metanephrines as per the recom-
mendation [5] for the initial biochemical assessment of PCC. This
approach has dominated as deconjugated metanephrines are present
at higher concentrations and are therefore easier to quantify. Despite
this there appears to be a lack of suitable Internal Quality Control
(IQC) material for these purposes as metanephrines present in com-
mercial quality control material are present almost entirely in their
free form [1,7]. Analytical targets supplied by manufacturers for
UMets are for methods that measure deconjugated UMets even though
the material does not assess the reproducibility of the deconjugation
process. Herein it is proposed that commercially available IQC and
calibrator material should contain balanced concentrations of free
and sulphated metanephrines to allow medical laboratories to assess
their analytical performances, this would improve the accuracy of
inter-laboratory assays. For the few laboratories measuring the free
UMets no commercial IQC targets are available and have to be deter-
mined in house, thus limiting the usefulness of the IQC material. Exter-
nal Quality Assurance (EQA) schemes in the United Kingdom on the
other hand do allow the few laboratories measuring the free fraction
to assess the recovery of free metanephrines spiked into pooled patient
samples. However results are compared to the majority of laboratories
that report total UMets and thus have limited value. Thus it appears
that IQC and EQA procedures are not ideally suited to themeasurement
of total or free urine metanephrines.
In order for free UMets to be measured more widely as part of the
initial screening process for PCC a larger evidence base is required.
Moreover commercially available IQC material must be made ﬁt for
this purpose by supplying free UMets targets. Moreover EQA schemes
should consider assessing the performance of laboratories measuring
free UMets separately from those measuring total UMets.
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